Clinical Trials Logo

Anticoagulant Adverse Reaction clinical trials

View clinical trials related to Anticoagulant Adverse Reaction.

Filter by:

NCT ID: NCT06401616 Recruiting - Atrial Fibrillation Clinical Trials

Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

Start date: May 21, 2024
Phase: Phase 4
Study type: Interventional

Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed. The ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention

NCT ID: NCT06187311 Recruiting - Atrial Fibrillation Clinical Trials

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

REVISE-AF
Start date: January 12, 2023
Phase: Phase 4
Study type: Interventional

In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction. It is a randomized, open-label, and phase 4 clinical trial to compare and evaluate efficacy and safety of Rivaroxaban. After obtaining informed consent to participate in this trial, screening is performed (Screening visit). Screening includes baseline 12-lead electrocardiography and laboratory tests to exclude severe end-organ dysfunction (such as renal dysfunction, liver dysfunction, or anemia). Baseline visits are available on the same day. After screening, subjects eligible for the trial will be randomly assigned (1:1 ratio) to Group 1 (15 mg of Rivaroxaban) or Group 2 (20 mg of Rivaroxaban) (Baseline visit). The study drug (Rivaroxaban 15mg or 20mg daily) will be administered for 12 months. During study period, a total of six visits (3,6,9,12 months) will be made, and follow-up test and outcome measurement will be done in each visit.

NCT ID: NCT06144866 Recruiting - Ischemic Stroke Clinical Trials

Evaluataion of NOAC Levels in Acute Stroke

Start date: May 1, 2020
Phase:
Study type: Observational [Patient Registry]
Read more »
NCT ID: NCT06108414 Not yet recruiting - Stroke Clinical Trials

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.

NCT ID: NCT06079021 Not yet recruiting - Sarcopenia Clinical Trials

COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device

COOLEY
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.

NCT ID: NCT05332158 Recruiting - Clinical trials for Adherence, Medication

Medicines Gaps Study

MeGa
Start date: May 30, 2022
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT04556188 Recruiting - Clinical trials for Rheumatic Heart Disease

The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa

RHD-CaSS
Start date: March 1, 2016
Phase:
Study type: Observational

In this bi-directional program of education, training and research activities based on sustainable development goals aim is to develop cardiac surgery service in Ethiopia. The aim is to evaluate the short and long-term outcome of cardiac surgery for rheumatic heart disease in a low-income country compared to individuals not offered cardiac surgery due to limited availability of the service. Second aim is to evaluate the quality of anticoagulant therapy in patients after cardiac surgery for rheumatic heart disease in a low-income country .

NCT ID: NCT04056143 Recruiting - Clinical trials for Anticoagulant Adverse Reaction

Precision Medicine Platform for Novel Oral Anticoagulants

Start date: January 2, 2019
Phase:
Study type: Observational

The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism. While the prescription of new oral anticoagulants (NOAC) has increasingly and largely replaced warfarin in accordance of better efficacy and safety, there are still adverse effects, including incidental minor and major bleeding, and inefficacy in thrombosis prevention. The overarching goal of this study is to develop a Pharmacogenomics Platform that is specifically designed for NOACs, in order to optimize and personalize the prescription and to facilitate the precision medicine.

NCT ID: NCT03926156 Terminated - Atrial Fibrillation Clinical Trials

RIvoraxaban in Mitral Stenosis

RISE MS
Start date: May 22, 2019
Phase: Phase 3
Study type: Interventional

In this randomized controlled clinical trial, patients with moderate to severe mitral valve stenosis (MS) and atrial fibrillation (AF) will be enrolled into the study.Participants will be divided into two groups based on the anticoagulation regimen type. The intervention group will receive rivaroxaban and the control group will be given warfarin. All patients will be observed closely during a period of one year. Through the follow up, embolic events and hemorrhagic complications will be recorded in both groups. In addition, patients in both group will undergo a baseline magnetic resonance imaging (MRI) and an MRI after one-year follow up, by which the silent embolic events will be compared in both groups.

NCT ID: NCT03297281 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)

SOAP
Start date: October 30, 2017
Phase: N/A
Study type: Interventional
Read more »